This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk" refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.

开始日期2024-12-31

申办/合作机构-

NCT06653972 / Not yet recruiting临床2期IIT

Efficacy and Safety of Liposomal Doxorubicin Combined with Vinorelbine in the Treatment of Advanced Metastatic Breast Cancer: a Single-Center, Prospective Phase II Clinical Study

With advancements in various treatment modalities, the survival of breast cancer patients has continuously improved. Patients with advanced breast cancer who have undergone multiple lines of therapy still have treatment options, but standard treatment protocols are lacking. Anthracyclines are a cornerstone in breast cancer treatment; however, their cumulative dose-related cardiac toxicity limits their use. Liposomal doxorubicin exhibits comparable efficacy to conventional anthracyclines and is not affected by previous cumulative doses. The combination of vinorelbine with liposomal doxorubicin shows reduced cross-toxicity, and several studies have demonstrated the effectiveness of this regimen in metastatic HER2-negative breast cancer patients.
Therefore, we aim to explore whether optimizing the dosage and treatment cycle of this combination therapy can provide a viable treatment option for metastatic HER2-negative breast cancer patients who have previously received second-line or higher chemotherapy, seeking a regimen that balances efficacy and safety.
This study is a single-center, single-arm Phase II clinical trial planned to enroll 30 metastatic HER2-negative breast cancer patients who have previously undergone second-line or higher chemotherapy. Participants will receive an optimized regimen of liposomal doxorubicin combined with vinorelbine, with safety assessed every cycle and efficacy evaluated every three cycles. Treatment will continue until radiographic evidence indicates disease progression, intolerable toxicity occurs, informed consent is withdrawn, or the investigator decides to discontinue treatment. Following treatment, each participant will undergo survival follow-up every three months until death, loss to follow-up, or withdrawal of consent.

开始日期2024-11-01

申办/合作机构

中国医学科学院肿瘤医院

[+1]

NCT06564038 / Not yet recruiting临床1/2期

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

开始日期2024-09-13

申办/合作机构

AstraZeneca PLC

100 项与 Doxorubicin liposomal 相关的临床结果

登录后查看更多信息

100 项与 Doxorubicin liposomal 相关的转化医学

登录后查看更多信息

100 项与 Doxorubicin liposomal 相关的专利（医药）

登录后查看更多信息

43,853

项与 Doxorubicin liposomal 相关的文献（医药）

2025-04-01·DEN open

Unique endoscopic features of primary biliary diffuse large B‐cell lymphoma: A case report with literature review (with video)

Article

作者: Ishigami, Keisuke ; Kameyama, Naohiro ; Nakase, Hiroshi ; Masaki, Yoshiharu ; Kawakami, Yujiro ; Sugawara, Taro ; Nakamura, Tomoya ; Satoh, Shuji ; Sugita, Shintaro ; Takada, Yumemi

Abstract:

A 67‐year‐old man visited our hospital complaining of dark‐colored urine and upper abdominal pain. Magnetic resonance cholangiopancreatography showed stricture of the distal bile duct, and contrast‐enhanced computed tomography showed irregular thickening of the distal bile duct wall. However, no enlarged lymph nodes, pancreatic tumors, or other neoplastic lesions were apparent around the bile duct. Endoscopic ultrasonography and intraductal ultrasonography showed irregular thickening of the inner hypoechoic layer without the disappearance of the innermost thin hyperechoic layer. On the basis of these findings, we considered that the bile duct lesion was of non‐epithelial origin. Thus, we repeatedly performed bile duct biopsies from the same site under fluoroscopy to obtain a sample of the submucosal tissue. The pathological diagnosis was diffuse large B‐cell lymphoma, and the patient received systemic chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). After six courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, positron emission tomography‐computed tomography showed the disappearance of 18‐fluorodeoxyglucose uptake in the bile duct and endoscopic retrograde cholangiography showed improvement of the bile duct stricture. Endoscopic findings and repeated biopsies were useful in making the diagnosis of primary biliary diffuse large B‐cell lymphoma.

2025-02-01·CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Cardioprotective Potential of Moringa Oleifera Leaf Extract Loaded Niosomes Nanoparticles - Against Doxorubicin Toxicity In Rats

Article

作者: Mohamed, Fatma Adel ; Ahmed, Samya Mahmoud ; Mohammed, Haitham S. ; Mohamad, Ebtesam A. ; Masoud, Marwa A.

Introduction::

Doxorubicin (DOX) is one of the most potent anticancer drugs that has ubiquitous usage in oncology; however, its marked adverse effects, such as cardiotoxicity, are still a major clinical issue. Plant extracts have shown cardioprotective effects and reduced the risk of cardiovascular diseases.

Method::

The current study is intended to explore the cardioprotective effect of ethanolic Moringa oleifera extracts (MOE) leaves loaded into niosomes (MOE-NIO) against DOXinduced cardiotoxicity in rats. MOE niosomes nanoparticles (NIO-NPs) were prepared and characterized by TEM. Seventy male Wistar rats were randomly divided into seven groups: control, NIO, DOX, DOX+MOE, DOX+MOE-NIO, MOE+DOX, and MOE-NIO+DOX. DOX (4 mg/kg, IP) was injected once per week for 4 weeks with daily administration of MOE or MOENIO (250 mg/kg, PO) for 4 weeks; in the sixth and seventh groups, MOE or MOE-NIO (250 mg/kg, PO) was administered one week before DOX injection. Various parameters were assessed in serum and cardiac tissue. Pre and co-treatment with MOE-NIO have mitigated the cardiotoxicity induced by DOX as indicated by serum aspartate aminotransferase (AST), creatine kinase - MB(CK-MB) and lactate dehydrogenase (LDH), cardiac Troponin 1(cTn1) and lipid profile. MOE-NIO also alleviated lipid peroxidation (MDA), nitrosative status (NO), and inflammatory markers levels; myeloperoxidase (MPO) and tumor necrosis factor-alpha (TNF-α) obtained in DOX-treated animals. Additionally, ameliorated effects have been recorded in glutathione content and superoxide dismutase activity. MOE-NIO effectively neutralized the DOXupregulated nuclear factor kappa B (NF-kB) and p38 mitogen-activated protein kinases (p38 MAPK), and DOX-downregulated nuclear factor-erythroid 2-related factor 2 (Nrf2) expressions in the heart.

Results::

It is concluded that pre and co-treatment with MOE-NIO could protect the heart against DOX-induced cardiotoxicity by suppressing numerous pathways including oxidative stress, inflammation, and apoptosis and by the elevation of tissue antioxidant status.

Conclusion::

Thus, it may be reasonable to suggest that pre and co-treatment with MOE-NIO can provide a potential cardioprotective effect when doxorubicin is used in the management of carcinoma.

2025-01-01·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Construction of robust protein nanocage by designed disulfide bonds for active cargo molecules protection in the gastric environment

Article

作者: Zhao, Guanghua ; Zhang, Tuo ; Gu, Chunkai ; Wang, Shujun ; Mi, Ya'nan ; Mi, Ya’nan

Notwithstanding the progress made, cargo molecules encapsulated within ferritin via oral administration in the gastric environment remains a persistent challenge. This study focuses on the strategic enhancement of ferritin stability in harsh gastric environment. By taking advantagie of computational-assisted design, we strategically introduced up to 96 disulfide bonds along three key inter-subunit interfaces to one single ferritin molecule with human H-chain ferritin and shrimp (Marsupenaeus japonicus) ferritin as starting materials, producing two kinds of robust ferritin nanocages with markedly enhanced acid and protease (pepsin and rennin) resistance. The crystal structure of ferritin nanocage confirmed our design at an atomic level. Encapsulation experiments demonstrated successful loading of bioactive cargo molecules (e.g., doxorubicin) into the engineered ferritin nanocages, with pronouncedly improved protection against leakage under acidic condition and the presence of pepsin and rennin as compared to their native counterparts. This study presents a potential approach for the design and engineering of protein nanocages for oral administration.

项与 Doxorubicin liposomal 相关的新闻（医药）

2024-09-05

·drugs

Doxorubicin + Trabectedin Tied to Increased Survival in Metastatic Leiomyosarcoma

THURSDAY, Sept. 5, 2024 -- For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and trabectedin is associated with improved overall and progression-free survival compared with doxorubicin alone, according to a study published online Sept. 4 in the New England Journal of Medicine . Patricia Pautier, M.D., from the Institut Gustave-Roussy in Villejuif, France, and colleagues conducted a phase 3 trial involving 150 patients with metastatic or unresectable leiomyosarcoma who had not received chemotherapy. Patients were randomly assigned to doxorubicin (six cycles) or doxorubicin plus trabectedin (six cycles), with continued trabectedin as maintenance therapy in patients in the doxorubicin-trabectedin group without disease progression. After six cycles of therapy, surgery was allowed to resect residual disease in each group. The researchers found that at a median follow-up of 55 months, 47 and 60 patients in the doxorubicin-trabectedin and doxorubicin groups, respectively, had died. Median overall survival was longer in the doxorubicin-trabectedin group versus the doxorubicin group (33 versus 24 months; adjusted hazard ratio for death, 0.65). Progression-free survival was longer in the doxorubicin-trabectedin group versus the doxorubicin group, in a finding consistent with earlier reports (12 versus six months; adjusted hazard ratio for progression or death, 0.37). "The trial results support the use of doxorubicin plus trabectedin for the first-line treatment of advanced or metastatic leiomyosarcomas, offering hope for improved outcomes in this challenging disease area," the authors write. The study was partially funded by PharmaMar, the manufacturer of trabectedin.

临床3期临床结果

2024-09-03

·同写意

XDC厮杀摁下快进键

ADC药物作为现在最主流的偶联疗法，正在肿瘤治疗中呈现烈火烹油之势。但市场代有新药出，ADC也终将会被新的偶联疗法迭代。目前来看，这个迭代趋势正在显著加快。多肽偶联疗法（PDC）作为一种全新偶联疗法，如果兼具ADC疗效的同时且有着显著优势的药代动力学特性、药效持续时间和大大减小的分子毒性，那么它是否能够形成对ADC药物的降维打击之势？目前来看，这个答案的验证已经并不遥远，进入中后期临床试验的管线，马上就将向我们展现它的优越性。 1 从ADC到PDC：全新疗法优势几何多肽偶联药物顾名思义，就是将有效毒素载荷通过连接子与多肽相连接，通过多肽的小分子、亲水性强的特点增加药物整体的水溶性，更容易到达细胞内，让其毒素载荷发挥毒性效应。与ADC相似，ADC主要由抗体，连接子和毒素载荷组成；PDC主要由多肽，连接子和毒素载荷组成。在有效载荷上，ADC与PDC没有太大差别。目前主要在使用小分子化学毒素payload，二代ADC的有效载荷为DNA损伤剂和微管蛋白抑制剂，三代ADC的有效载荷为DNA拓扑异构酶I抑制剂。虽然理论上来说万物可联，但目前以及可预见的未来，ADC和PDC的载荷都是以化学小分子为主。例如目前进展较快的管线AEZS-108，也是以阿霉素类毒素Doxorubicin作为载荷分子，这是第三代ADC的主流payload。主要的差异，在抗体与多肽的定位上。众所周知，ADC作为大分子，目前主要是通过抗体蛋白来靶向定位癌细胞上的特异性靶点，然后以特有的大分子蛋白进入细胞的形式——内吞来被癌细胞吸收，最后进入溶酶体溶解以发挥特有的毒性效应。因此，ADC药物的关键在于靶点的选择上：选择那些在特定癌细胞上过度表达的靶点，例如现在的HER2，trop2等，令抗体能够精准定位。而PDC不同，多肽本身的分子量并不大。可以根据其功能分为细胞穿透肽（CPPs）、细胞靶向肽（CTPs）、自组装肽（SAPs）和反应肽。目前发展较为主流的为前两种。CPPs分子量小，大约在30个氨基酸以下，进入细胞的方式既有直接进入（分子量小）和内吞，但其的特异性较低。而CTPs相反，它本身主要是通过识别特定细胞上的一些特异性位点从而定位细胞并被内吞进入其中，而这也让其拥有较强的特异性。进入细胞后，在溶酶体中裂解而发挥毒素作用。此外，运用环肽去靶向而不是线性肽，也有重要的技术考量。首先相比于线性多肽，环肽的稳定性得到大大提升：线形肽的末端会再两侧分别保留氨基和羧基，而环肽的环化则完全避免了这一点，从而有效避免外肽酶对末端游离基团的水解效应，而这是环肽得以存在的基础。其次，由于环状结构导致的构象变化限制，环肽类化合物一般具有较大的表面积，从而使其与靶点蛋白间具有高度亲和力及识别特异性。最后，环肽由于分子量小，因此需要有穿过非极性细胞膜的考量，而其分子内形成的氢键可以起到对极性表面的遮盖，从而达到增强分子的脂溶性来增强对细胞膜的渗透性。结构的不同造就了功能的不同。首先，PDC由于较小的分子量，令其有着非常良好的渗透性。以BCYC的BT5528为例，其为双肽环，仅仅包括9-20个氨基酸，分子量仅为2kDa，仍然属于化学药物的范畴。作为对比，抗体由两条轻链和两条重链组成，分子量为150kDa。ADC药物由于抗体这个庞然大物，体内循环与进入实体瘤的渗透都不如分子量远远小于它的PDC。此外，在血浆内的半衰期，环肽也远比线性肽有优势。其次是分子量小的多肽拥有着较低的生产成本。生产PDC比生产ADC工艺次序简洁很多，且其纯化，保存，质控也更加容易。对于PDC而言，多肽的制备主要是应用多肽固相合成技术，近年来由于司美格鲁肽等减肥药的火爆，多肽固相合成一直在扩充产能，国内的头部CXO药明康德在2024年H1报告中显示，其2024年产能已经达到32000L。较低的成本赋予了其未来大规模生产打下价格的想象力空间。但它的想象力空间还可以更大。RDC和PDC都是目前ADC之后新一代的偶联方法，而基于环肽上述优势的原因，将二者结合，或许是未来RDC药物的主要发展形式。目前目前为止，已批准上市的9个治疗以及诊断的RDC药物中，其中4款为环肽RDC。以诺华在治疗性RDC的看山之作——Lutathera来看，其用于胃肠胰腺神经内分泌肿瘤治疗与诊断。销售额2023年已达到6亿美元，而销售峰值预期将超过10亿美元。并且未来的RDC设计来看，也将会以环肽形式为主。 2 PDC先驱者之一：Bicycle Therapeutics Bicycle Therapeutics（BCYC）成立于2017年，上市于2019年，市值从2021年的17亿美元到低谷的4亿美元，而从今年开始重新崛起，回到了17亿美元左右的市值。目前其进展最快的管线为BT8009，靶点为ADC药物的热门靶点之一：nectin-4:，适应症为治疗UC (尿路上皮癌)。目前BT8009不仅在美国，加拿大等地进入了III期临床阶段，同时在今年7月完成了在中国申报临床试验的工作。 BT8009相比于nectin-4 ADC而言，在体内的分布和代谢更加类似于化学小分子药物，拥有代谢时间快，半衰期短的特点。并且其清除途径主要通过肾脏和肝脏代谢，与传统化药类似，避免了类似抗体的复杂的代谢路径以及可能产生的潜在毒副作用。此外，有较多证据表明，ADC耐药性可能通过抗原内化、内吞/溶酶体加工或溶酶体释放的毒素释放到细胞质中的变化而产生。由于BTC不一定需要内化以释放毒素，因此它们可以避免这些耐药机制。而临床数据方面，它将要直接面对的对手，是当前nectin-4 ADC中的rising star——padcev。在2023年AACR GU会议上，Bicylce公布了早期临床——Duravelo-1中BT8009剂量递增队列（Part A-1）临床数据。患者基线上，24例为尿路上皮癌（UC）患者，UC患者中100%接受过PD-(L)1抑制剂治疗。在尿路上皮癌中，ORR为38%，DCR为54%。而Enfortumab Vedotin在III临床研究中展现的结果为ORR（40.6%）和DCR（71.9%），患者基线方面，padcev的患者也全部接受过PD-(L)1治疗，非头对头毕竟可以说略逊一筹，不过，早期临床和III期临床的样本量不能想提并论，样本量少会导致较大误差。而其安全性则略胜Padcev一筹，这在今年ASCO会议上也有所展示。截至2024年3月22日，BT8009的3级及以上TRAEs发生率为31%；而Padcev在III期临床研究中3级及以上TRAEs发生率为51.4%。当然，这样需要BT8009后期的大样本临床数据验证。今年1月，BCYC启动了Duravelo-2这项大样本临床，预计入组900多名患者，有着一战定胜负直接上市的决心。乐观预计该药将于2027-2028年上市。根据市场对其预测，其销售峰值大约在27-34亿美金，这与Padcev的销售峰值相当。但考虑到BT8009的成产成本比ADC药物更加低廉，盈利能力将胜过Padcev。 BCYC的另一条核心管线是BT5528，该药目前处于II期临床阶段。其靶点为EphA2。EphA2被作为靶点的想象力由来已久，但在ADC药物的开发上并不理想。最典型的是Medi-547，由于EphA与血管生成相关，它被靶向后，出现了严重的出血和凝血的副作用，不得不停止临床试验。但这个ADC上失败的靶点却在PDC上枯木逢春。根据BT5528的安全性结果显示，其没有出现严重出血事件，也没出现，皮肤、神经等方面的严重副作用，不过不良反应与BT8009类似。而BCYC的想象力还不止于此。2023年5月，拜耳宣布与BCYC合作，利用BCYC的环肽偶联技术，开发下一代类似从ADC到RDC迭代的疗法——将多肽偶联与放射性疗法结合。该次合作，BCYC将获得拜耳达到17亿美元的潜在里程碑付款。 3 PeptiDream：多家MNC的合作宠儿如果说BCYC主要自身管线的积极临床数据获得正面的股价催化，那么peptiDream则是另一种PDC药企形式——通过自身独特的技术平台与各家MNC合作，来发展自身的企业。 PeptiDream成立于2006年，是一家做核药与多肽起价的biotech。PeptiDream的一大特色是其独有的环肽技术平台——Proprietary Drug Discovery Platform - System(PDPS)。能够生成高度多样化的大环肽化合物库，可以针对几乎全部有价值的生物靶标进行筛选。PDPS是目前已知的最大规模环肽生成库之一，可以生成数万亿个具有无限化学多样性的大环肽，这些肽在无细胞的系统中合成，效率相比传统方式极其高。此外，所有的多肽都用各自的mRNA/CDA标签“条形码”。而条形码可以大大提高药物发现效率。其可用于在层层选择中不停筛出高新亲和性的环肽，并允许快速识别高亲和性肽的氨基酸序列。近期在诺华在核药上的合作，便是一次极其有看点的前沿技术组合。今年4月底，诺华与PeptiDream达成合作协议，共同开发多款大环态靶向偶联核药。作为核药龙头，诺华的治疗性RDC药物也被视为ADC之后的热门偶联药物放向之一，而将其与环肽结合，则或许会是RDC之后又一次成功的迭代。这次的合作，令peptidream将获得了1.8亿美元前期付款，而之后的开发和商业化里程碑付款高达27.1亿美元。与其它多家MNC在肽类上的巨额合作，更是令其声名鹊起。 2022年12月22日，PeptiDream宣布与默克合作，共同开发PDC药物。潜在总额高达21亿美元。 2022年12月26日，PeptiDream宣布与礼来展开合作，共同开发PDC药物，PeptiDream将负责肽的创建和优化，而礼来则负责有效载荷的创建和优化。此次交易的预付款就达到了12.35亿美元。而另外的各种肽类药物的开发则更多。这是PeptiDream与BCYC不同的原因，它有着非常深厚的底蕴积累，以及成熟的环肽技术平台，可以和多家MNC以合作形式共同开发PDC药物。由于其经营模式的原因，它自身的管线推进并不没有其它烧钱的biotech那样迅速。目前进展最快的两款PDC管线靶点为PD-1，与BMS合作，处在临床I期阶段。以BMS-986229为例，它是一款与BMS合作的核药诊断试剂，可特异性结合表达 PD-L1 的癌细胞，用于确定癌症患者使用检查点抑制剂治疗的情况，但该管线推进较为缓慢，2019年进入临床，目前仍处于临床I期。其股价催化，目前来看仍然在与各家MNC的大额合作协议上。结语：PDC作为全新的治疗手段，在许多方面都有着比ADC更加略胜一筹的优势，目前其成本的降低与利润的提高是非常值得期待的地方，也许会引领药企进入一个盈利的新时代！同写意媒体矩阵，欢迎关注↓↓↓

抗体药物偶联物多肽偶联药物临床结果

2024-06-17

·GlobeNewswire-Health Care

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy1 This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCL Data were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking oral presentation 15 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) versus MabThera®/Rituxan® (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy.1 Data were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at the European Hematology Association (EHA) 2024 Congress as a late-breaking oral presentation.1 "The results from STARGLO are the first to show the potential of a CD20xCD3 bispecific antibody to make a difference in second or later-line DLBCL in people who are ineligible for transplant and have limited options," said Jeremy Abramson, M.D., Director, Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, and principal investigator of the STARGLO study. "Glofitamab in combination with GemOx showed clinically significant improvement in overall survival, as well as key secondary endpoints, and the benefits were reinforced with an additional 11 months of follow-up.” The primary analysis (median follow-up of 11.3 months) confirmed that the study met its primary endpoint of overall survival (OS), demonstrating that patients treated with Columvi plus GemOx lived significantly longer, with a 41% reduction in the risk of death (hazard ratio [HR]=0.59, 95% CI: 0.40-0.89, p=0.011) versus R-GemOx.1 Median OS was not reached with the Columvi regimen versus nine months for R-GemOx.1 Safety of the combination appeared consistent with the known safety profiles of the individual medicines. Pre-specified exploratory subgroup analyses showed comparable results, including consistency across the clinically relevant stratification factors of line of therapy (second-line versus third-line+) and outcome of last therapy (relapsed versus refractory). Regional inconsistencies were observed, however interpretation is limited given the exploratory nature of these analyses and small subgroups with wide confidence intervals. “This marks a first step in advancing Columvi combinations in earlier settings to address the urgent need for the 40% of people who will relapse or have refractory disease and who have limited options,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Moreover, patients do not have to wait to start treatment with Columvi. This could be particularly important for patients with highly aggressive disease who are at risk of rapid disease progression.” The Columvi combination also met its key secondary endpoints, with a 63% reduction in risk of disease worsening or death (progression-free survival, PFS) compared to R-GemOx (HR=0.37; 95% CI: 0.25–0.55, p1 A follow-up analysis was conducted after all patients had completed therapy (median follow-up of 20.7 months), which showed continued benefit in both primary and secondary endpoints.1 Median OS for people treated with the Columvi combination was 25.5 months, nearly double what was seen for people treated with R-GemOx at 12.9 months, and more than twice as many patients experienced a complete response (58.5% versus 25.3%, respectively).1 Adverse event (AE) rates were higher with the Columvi combination versus R-GemOx, noting higher median number of cycles received with Columvi combination (11 versus 4). One of the most common AEs was cytokine release syndrome, which was generally low grade (Any Grade: 44.2%, Grade 1: 31.4%, Grade 2: 10.5%, Grade 3: 2.3%) and occurred primarily in Cycle 1.1 Columvi is the first CD20xCD3 bispecific antibody to demonstrate a survival benefit in DLBCL in a randomised Phase III trial, demonstrating the potential of this type of therapeutic combination to improve survival outcomes in earlier lines of treatment. The standard second-line therapy for R/R DLBCL patients has historically been high-dose chemotherapy followed by stem-cell transplant, however, not everyone with R/R DLBCL is a candidate due to age or coexisting medical conditions. Newer therapies are also becoming available, but barriers remain for many, and alternative treatment options are needed for these patients. Columvi is given as a fixed-duration treatment, offering people with R/R DLBCL a treatment end date and the possibility of a treatment-free period, unlike continuous treatments. Results from the STARGLO study will be submitted to global health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency. Columvi is also being investigated in other aggressive, hard-to-treat lymphomas and was recently granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior therapies based on results from the Phase I/II NP30179 study. The STARGLO study [GO41944; NCT04408638] is a Phase III, multicentre, open-label, randomised study evaluating the efficacy and safety of Columvi® (glofitamab) in combination with gemcitabine plus oxaliplatin (GemOx) versus MabThera®/Rituxan® (rituximab) in combination with GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and who are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy.2 Outcome measures include overall survival (primary endpoint), progression-free survival, complete response rate, objective response rate, duration of objective response (secondary endpoints), and safety and tolerability.2 STARGLO is intended as a confirmatory study to convert Columvi’s accelerated approval in the US and conditional marketing authorisation in the EU to full approvals for people with R/R DLBCL after two or more lines of systemic therapy based on the pivotal Phase I/II NP30179 study. Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T-cells and CD20 on the surface of B-cells. Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T-cells, a type of immune cell, and two regions that bind to CD20, a protein on B-cells, which can be healthy or malignant. This dual-targeting brings the T-cell in close proximity to the B-cell, activating the release of cancer cell-killing proteins from the T-cell. Columvi is part of Roche’s broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development programme that also includes Lunsumio® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Roche is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma (DLBCL) and other blood cancers. This includes the Phase III SKYGLO [NCT06047080] trial investigating Columvi in combination with Polivy® (polatuzumab vedotin), MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin and prednisone in previously untreated DLBCL. DLBCL is the most common form of non-Hodgkin lymphoma (NHL), accounting for about one in three cases of NHL.3 DLBCL is an aggressive (fast-growing) type of NHL.3 While it is generally responsive to treatment in the frontline, as many as 40% of people will relapse or have refractory disease, at which time salvage therapy options are limited and survival is short.4 Improving treatments earlier in the course of the disease and providing much needed alternative options could help to improve long-term outcomes. Approximately 160,000 people worldwide are diagnosed with DLBCL each year.3,5 Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), Lunsumio® (mosunetuzumab) and Columvi® (glofitamab). Our pipeline of investigational haematology medicines includes T-cell engaging bispecific antibody cevostamab, targeting both FcRH5 and CD3, Tecentriq® (atezolizumab), and crovalimab, an anti-C5 antibody engineered to optimise complement inhibition. Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further. Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. References [1] Abramson J, et al. Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Global Randomized Phase III trial (STARGLO). Presented at: EHA Hybrid Congress; 2024 Jun 3-16. Abstract #LB3438. [2] ClinicalTrials.gov. A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: NCT04408638 [Internet; cited May 2024]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04408638. [3] UpToDate. Patient education: Diffuse large B cell lymphoma in adults (Beyond the Basics). [Internet; cited May 2024]. Available from: https://www.uptodate.com/contents/diffuse-large-b-cell-lymphoma-in-adults-beyond-the-basics. [4] Sehn LH, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-858. [5] World Health Organization. Numbers derived from GLOBOCAN 2022. Non-Hodgkin Lymphoma Factsheet [Internet; cited May 2024]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf.

$Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma$

临床结果突破性疗法免疫疗法上市批准

100 项与 Doxorubicin liposomal 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00997

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
乳腺癌	欧盟	Accord Healthcare SLU	2022-05-31
乳腺癌	冰岛	Accord Healthcare SLU	2022-05-31
乳腺癌	列支敦士登	Accord Healthcare SLU	2022-05-31
乳腺癌	挪威	Accord Healthcare SLU	2022-05-31
转移性乳腺癌	欧盟	Baxter Holding BV	1996-06-20
转移性乳腺癌	冰岛	Baxter Holding BV	1996-06-20
转移性乳腺癌	列支敦士登	Baxter Holding BV	1996-06-20
转移性乳腺癌	挪威	Baxter Holding BV	1996-06-20
多发性骨髓瘤	欧盟	Baxter Holding BV	1996-06-20
多发性骨髓瘤	冰岛	Baxter Holding BV	1996-06-20
多发性骨髓瘤	列支敦士登	Baxter Holding BV	1996-06-20
多发性骨髓瘤	挪威	Baxter Holding BV	1996-06-20
艾滋病相关性卡波西肉瘤	美国	Baxter Healthcare Corp.	1995-11-17
卵巢癌	美国	Baxter Healthcare Corp.	1995-11-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	临床3期	美国	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	中国	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	加拿大	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	德国	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	中国香港	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	意大利	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	马来西亚	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	菲律宾	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	新加坡	Imunon, Inc.	2014-06-01
肝细胞癌	临床3期	韩国	Imunon, Inc.	2014-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02112656 (OPTIMA, CTgov)	临床3期	肝细胞癌 \| 不可切除的肝细胞癌	554	ThermoDox (ThermoDox 50 mg/m2)	繭鹽觸積鏇壓餘繭築窪(艱餘願蓋鏇築壓夢製衊) = 遞醖築鹽窪糧簾鹽鏇蓋壓遞蓋繭窪憲餘繭築蓋 (壓製範憲窪鏇積衊簾鹹, 憲餘壓觸築積鹽構選觸 ~ 廠餘蓋顧蓋艱範選淵網) 更多	-	2024-08-20
				Dummy infusion (Dummy Infusion)	繭鹽觸積鏇壓餘繭築窪(艱餘願蓋鏇築壓夢製衊) = 膚憲製齋憲蓋壓襯廠壓壓遞蓋繭窪憲餘繭築蓋 (壓製範憲窪鏇積衊簾鹹, 範鹽鑰膚積壓網醖鬱網 ~ 構糧艱醖糧範觸鏇遞顧) 更多
ESMO_SRC2024 人工标引	N/A	卡波西肉瘤一线	54	Liposomal doxorubicin	遞憲齋餘蓋築選觸鏇鹹(遞構獵憲選顧餘鹽糧醖) = 糧憲鹽顧糧鹹構築鬱製蓋鏇鹽遞獵鏇鏇壓鏇簾 (艱鹹淵獵鏇襯憲艱鑰膚 ) 更多	积极	2024-03-15
				Liposomal doxorubicinPaclitaxel	遞憲齋餘蓋築選觸鏇鹹(遞構獵憲選顧餘鹽糧醖) = 構窪範衊夢製衊構製鹹蓋鏇鹽遞獵鏇鏇壓鏇簾 (艱鹹淵獵鏇襯憲艱鑰膚 ) 更多
NCT01990352 (CTgov)	临床2期	转移性乳腺癌	24	Pegylated liposomal doxorubicin	選膚餘願壓鏇憲夢膚鬱(遞窪願憲鹽構膚艱廠鏇) = 網餘鹹製繭衊糧願艱觸壓遞膚網顧鹽鹹鏇廠膚 (廠齋獵憲簾簾鑰艱繭構, 廠齋觸遞夢襯衊築廠淵 ~ 遞選衊醖襯淵鏇構衊窪) 更多	-	2023-10-26
ESMO2023	N/A	肉瘤一线 \| 三线	21	Pegylated liposomal doxorubicin (PLD) plus trabectedin	顧鏇蓋選繭鏇鏇襯獵鑰(憲廠鏇憲鏇憲觸獵襯壓) = 範淵鬱鹹膚壓構鏇願醖艱鏇鹽廠襯醖餘鏇廠範 (廠範鹹鹽願壓衊夢顧衊 ) 更多	-	2023-10-23
NCT05551507 (ESMO2023) 人工标引	临床1期	卵巢癌	61	IN10018+pegylated liposomal doxorubicin	築簾蓋顧糧糧鏇衊範憲(鹽糧積襯構鏇鑰鑰膚醖) = 繭築糧願餘夢襯醖願鏇膚壓膚壓顧蓋鏇衊願廠 (廠醖選築齋壓鏇醖願壓 ) 更多	积极	2023-10-22
#863 (ESGO2023)	N/A	卵巢上皮癌	103	Pegylated liposomal doxorubicin (PLD)	願願壓淵膚鑰簾鑰鏇製(餘繭網齋築積糧衊鬱壓) = at cycle 2 = 6%; cycle 3 = 11%; cycle 4 = 17%; cycle 5 = 20% (trend significant between cycles 2 and 4, P = 0.03) 簾積襯願構廠夢膚製觸 (願襯鬱憲蓋網醖繭襯顧 )	-	2023-09-27
				Weekly paclitaxel (WP)
ESGO2023	N/A	肉瘤	21	Pegylated liposomal doxorubicin + Trabectedin	齋壓蓋網夢網鏇衊鏇糧(夢醖艱襯範簾夢壓鏇齋) = 簾鏇壓艱鏇壓願製窪窪顧顧廠範鏇觸網壓鏇製 (鏇廠鏇繭膚範壓衊鹽衊 ) 更多	-	2023-09-27
#1036 (ESGO2023)	N/A	卵巢癌	67	Gemcitabine + platine derives ± bevacizumab	鬱壓顧窪糧獵鬱鬱蓋襯(鹹蓋鏇膚夢蓋艱願壓鹽) = 鑰獵餘糧構衊窪願獵膚壓窪網膚膚簾廠齋獵廠 (襯鹹網繭襯衊簾製簾鑰 ) 更多	-	2023-09-27
				Liposomal doxorubicin + platine derives ± bevacizumab	鬱壓顧窪糧獵鬱鬱蓋襯(鹹蓋鏇膚夢蓋艱願壓鹽) = 餘簾觸壓積簾繭襯窪鑰壓窪網膚膚簾廠齋獵廠 (襯鹹網繭襯衊簾製簾鑰 ) 更多
SOHO2023	临床2期	继发性中枢神经系统淋巴瘤 BCR signaling \| BTK-responsive tumors \| CD10-negative	49	TEDDI-R + Ibrutinib	廠鏇壓鬱願壓壓築積觸(淵顧鏇網鑰廠衊築壓觸) = 壓鑰選窪醖艱壓醖壓觸鏇獵齋顧鹹窪襯憲夢餘 (廠願網壓鹹選願構願範 ) 更多	积极	2023-09-01
				TEDD-R (no ibrutinib)	顧壓構糧鏇願餘醖製遞(選蓋簾願襯醖遞願選餘) = 艱積鑰網淵遞範襯觸糧製鏇網鏇選願糧糧鏇廠 (獵蓋鏇鏇鏇網獵築網遞 ) 更多
ICML2023	临床2期	复发性经典霍奇金淋巴瘤 \| 弥漫性大B细胞淋巴瘤	92	R-COMP-DI	醖顧簾夢壓壓鬱遞憲網(憲鬱襯壓窪醖窪繭繭艱) = very small changes, i.e. <10% point reductions in median values of GLS and LVEF at interim, EoT and 6-month follow-up, when they were compared with the median values at baseline 鹽壓廠觸網鏇簾糧構膚 (鑰餘蓋鑰網製獵築膚淵 )	积极	2023-06-09